$SPRO
Spero Therapeutics Inc

2023 Q3 Form 10-Q Financial Statement

#000095017023041314 Filed on August 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $25.47M $2.716M
YoY Change 1169.84% 36.28%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.710M $6.096M
YoY Change -13.9% -24.28%
% of Gross Profit
Research & Development $16.39M $9.510M
YoY Change 122.73% 16.36%
% of Gross Profit
Depreciation & Amortization $110.0K $108.0K
YoY Change -57.2% -63.27%
% of Gross Profit
Operating Expenses $27.41M $15.61M
YoY Change 98.03% -44.41%
Operating Profit -$1.934M -$12.89M
YoY Change -83.66% -50.58%
Interest Expense $950.0K $982.0K
YoY Change 421.98% -0.71%
% of Operating Profit
Other Income/Expense, Net $940.0K $976.0K
YoY Change 491.19% -137.51%
Pretax Income -$990.0K -$11.91M
YoY Change -91.52% -58.46%
Income Tax $2.200M
% Of Pretax Income
Net Earnings -$3.200M -$11.90M
YoY Change -72.65% -58.54%
Net Earnings / Revenue -12.56% -438.14%
Basic Earnings Per Share -$0.06 -$0.23
Diluted Earnings Per Share -$0.06 -$0.23
COMMON SHARES
Basic Shares Outstanding 52.70M 52.57M
Diluted Shares Outstanding 52.71M 52.57M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $93.80M $77.69M
YoY Change 85.94% 71.12%
Cash & Equivalents $93.83M $77.69M
Short-Term Investments
Other Short-Term Assets $5.400M $8.571M
YoY Change 262.9% 72.28%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $102.2M $88.35M
YoY Change 93.28% 70.05%
LONG-TERM ASSETS
Property, Plant & Equipment $41.00K $148.0K
YoY Change -91.7% -76.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $434.0K $5.740M
YoY Change -92.44% 4.99%
Total Long-Term Assets $4.879M $10.54M
YoY Change -57.9% -9.75%
TOTAL ASSETS
Total Short-Term Assets $102.2M $88.35M
Total Long-Term Assets $4.879M $10.54M
Total Assets $107.1M $98.89M
YoY Change 66.11% 55.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.103M $1.310M
YoY Change -57.28% -23.44%
Accrued Expenses $8.300M $7.305M
YoY Change -15.1% -27.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.46M $17.32M
YoY Change 56.92% 21.75%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $27.90M $26.78M
YoY Change 76.95% 98.72%
Total Long-Term Liabilities $27.90M $26.78M
YoY Change 76.95% 98.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.46M $17.32M
Total Long-Term Liabilities $27.90M $26.78M
Total Liabilities $53.40M $44.10M
YoY Change 66.9% 59.19%
SHAREHOLDERS EQUITY
Retained Earnings -$442.3M -$439.1M
YoY Change 0.39% 2.35%
Common Stock $496.0M $493.8M
YoY Change 4.83% 6.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $53.71M $54.78M
YoY Change
Total Liabilities & Shareholders Equity $107.1M $98.89M
YoY Change 66.11% 55.41%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$3.200M -$11.90M
YoY Change -72.65% -58.54%
Depreciation, Depletion And Amortization $110.0K $108.0K
YoY Change -57.2% -63.27%
Cash From Operating Activities $15.92M -$18.56M
YoY Change -1763.53% -19.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 220.0K 0.000
YoY Change -96.41% -100.0%
NET CHANGE
Cash From Operating Activities 15.92M -18.56M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 220.0K 0.000
Net Change In Cash 16.14M -18.56M
YoY Change 219.92% -30.5%
FREE CASH FLOW
Cash From Operating Activities $15.92M -$18.56M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001701108
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2022Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38266
dei Entity Registrant Name
EntityRegistrantName
SPERO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-4590683
dei Entity Address Address Line1
EntityAddressAddressLine1
675 Massachusetts Avenue,
dei Entity Address Address Line2
EntityAddressAddressLine2
14th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
dei Local Phone Number
LocalPhoneNumber
242-1600
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
SPRO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52696289
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77690000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
109107000
CY2023Q2 us-gaap Other Receivables
OtherReceivables
2088000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
1084000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8571000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3379000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
88349000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
113570000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
148000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
368000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4648000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5124000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5740000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5740000
CY2023Q2 us-gaap Assets
Assets
98885000
CY2022Q4 us-gaap Assets
Assets
124802000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1310000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
617000
CY2023Q2 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5601000
CY2022Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8973000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1704000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1690000
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8709000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10369000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17324000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21649000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4407000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4957000
CY2023Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
22300000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
22166000
CY2023Q2 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
72000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
96000
CY2023Q2 us-gaap Liabilities
Liabilities
44103000
CY2022Q4 us-gaap Liabilities
Liabilities
48868000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52571813
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52571813
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52456195
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52456195
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
53000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
52000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
493787000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
489760000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-439058000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-413878000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54782000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
75934000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98885000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124802000
CY2023Q2 spro Grant Revenue
GrantRevenue
1928000
CY2022Q2 spro Grant Revenue
GrantRevenue
1097000
spro Grant Revenue
GrantRevenue
3258000
spro Grant Revenue
GrantRevenue
2919000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
788000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
896000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1528000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1143000
CY2023Q2 us-gaap Revenues
Revenues
2716000
CY2022Q2 us-gaap Revenues
Revenues
1993000
us-gaap Revenues
Revenues
4786000
us-gaap Revenues
Revenues
4062000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9510000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8173000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18489000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25144000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6096000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8051000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13413000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23356000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
11849000
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
11849000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
15606000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
28073000
us-gaap Operating Expenses
OperatingExpenses
31902000
us-gaap Operating Expenses
OperatingExpenses
60349000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12890000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-26080000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27116000
us-gaap Operating Income Loss
OperatingIncomeLoss
-56287000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
982000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
111000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1944000
us-gaap Investment Income Interest
InvestmentIncomeInterest
183000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-8000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
CY2023Q2 spro Interest Expense Related To The Sale Of Future Royalties
InterestExpenseRelatedToTheSaleOfFutureRoyalties
0
CY2022Q2 spro Interest Expense Related To The Sale Of Future Royalties
InterestExpenseRelatedToTheSaleOfFutureRoyalties
-117000
spro Interest Expense Related To The Sale Of Future Royalties
InterestExpenseRelatedToTheSaleOfFutureRoyalties
0
spro Interest Expense Related To The Sale Of Future Royalties
InterestExpenseRelatedToTheSaleOfFutureRoyalties
-2605000
CY2023Q2 spro Loss On Extinguishment Of Liability Related To The Sale Of Future Royalties
LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties
0
CY2022Q2 spro Loss On Extinguishment Of Liability Related To The Sale Of Future Royalties
LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties
3581000
spro Loss On Extinguishment Of Liability Related To The Sale Of Future Royalties
LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties
0
spro Loss On Extinguishment Of Liability Related To The Sale Of Future Royalties
LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties
3581000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
995000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
802000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
976000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2602000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1936000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5224000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11914000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28682000
us-gaap Profit Loss
ProfitLoss
-25180000
us-gaap Profit Loss
ProfitLoss
-61511000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52571813
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52571813
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32977807
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32977807
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52549538
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52549538
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32793288
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32793288
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11914000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28682000
us-gaap Profit Loss
ProfitLoss
-25180000
us-gaap Profit Loss
ProfitLoss
-61511000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
6000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11914000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-28676000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25180000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61509000
us-gaap Profit Loss
ProfitLoss
-25180000
us-gaap Profit Loss
ProfitLoss
-61511000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
221000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
483000
spro Non Cash Lease Cost
NonCashLeaseCost
476000
spro Non Cash Lease Cost
NonCashLeaseCost
218000
us-gaap Share Based Compensation
ShareBasedCompensation
4027000
us-gaap Share Based Compensation
ShareBasedCompensation
4520000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-7000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-13000
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-0
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
802000
spro Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
0
spro Non Cash Interest Expense Associated With The Sale Of Future Royalties
NonCashInterestExpenseAssociatedWithTheSaleOfFutureRoyalties
2605000
spro Loss On Extinguishment Of Liability Related To The Sale Of Future Royalties
LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties
0
spro Loss On Extinguishment Of Liability Related To The Sale Of Future Royalties
LossOnExtinguishmentOfLiabilityRelatedToTheSaleOfFutureRoyalties
3581000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1004000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1054000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5192000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3646000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-905000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
693000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
612000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3372000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5839000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1526000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-393000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-24000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-21000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-536000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-334000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31417000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51256000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
26970000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
60777000
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-129000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
33936000
spro Repayment Of Liability Related To The Sale Of Future Royalties
RepaymentOfLiabilityRelatedToTheSaleOfFutureRoyalties
0
spro Repayment Of Liability Related To The Sale Of Future Royalties
RepaymentOfLiabilityRelatedToTheSaleOfFutureRoyalties
54485000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4203000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
419000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-49863000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31417000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-67183000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
109107000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
112584000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
77690000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45401000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
64839000
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
0
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1857000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11914000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54782000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
75934000
us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4027000
us-gaap Profit Loss
ProfitLoss
-25180000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54782000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
62473000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
231000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
577000
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1317000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
6000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28682000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
35923000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
88289000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
419000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4203000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4520000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000
us-gaap Profit Loss
ProfitLoss
-61511000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
35923000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11900000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-28700000
us-gaap Net Income Loss
NetIncomeLoss
-25200000
us-gaap Net Income Loss
NetIncomeLoss
-61500000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-439100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, revenue recognition, the accrual for clinical trial costs and other research and development expenses and the valuation of share-based awards. There may be changes to those estimates in future periods. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Actual results may differ from those estimates or assumptions.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains most of its cash and cash equivalents at one accredited financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">June 30, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and December 31, 2022, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.</span></span></p>
us-gaap Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
As of June 30, 2023, and December 31, 2022, the Company had no off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements.
CY2023Q2 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2022Q4 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2023Q2 spro Percentage Of Tax Benefit Recognized
PercentageOfTaxBenefitRecognized
0.50
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
800000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
900000
spro Fair Value Liabilities Of Level2 To Level1 Transfers Amount
FairValueLiabilitiesOfLevel2ToLevel1TransfersAmount
0
CY2023Q2 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
2671000
CY2022Q4 spro Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1823000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1663000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5797000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1065000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
696000
CY2023Q2 spro Accrued Restructuring Expenses
AccruedRestructuringExpenses
39000
CY2022Q4 spro Accrued Restructuring Expenses
AccruedRestructuringExpenses
448000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
163000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
209000
CY2023Q2 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
5601000
CY2022Q4 spro Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
8973000
spro Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.95
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3979099
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.99
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y3M7D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
46413
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.74
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
298773
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.5
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3726739
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y11M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3726739
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y11M12D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3024800
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.08
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P4Y3M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
11595127
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2084763
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1857000
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1317000
us-gaap Share Based Compensation
ShareBasedCompensation
4027000
us-gaap Share Based Compensation
ShareBasedCompensation
4520000
us-gaap Profit Loss
ProfitLoss
-61511000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11914000
CY2023Q2 spro Milestone Payment Upon Submission Of A New Drug Application
MilestonePaymentUponSubmissionOfANewDrugApplication
225000000
CY2023Q2 spro Sales Milestone Events
SalesMilestoneEvents
1000000000
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Restructuring Charges
RestructuringCharges
0
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
11849000
us-gaap Restructuring Charges
RestructuringCharges
11849000
CY2023Q2 spro Outstanding Accrued Expense
OutstandingAccruedExpense
100000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
448000
us-gaap Restructuring Charges
RestructuringCharges
0
us-gaap Payments For Restructuring
PaymentsForRestructuring
409000
us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
0
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
39000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-11914000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-28682000
us-gaap Profit Loss
ProfitLoss
-25180000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28682000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25180000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-61511000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52571813
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52571813
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32977807
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32977807
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52549538
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52549538
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32793288
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32793288
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8492086
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9892234
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8492086
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9892234

Files In Submission

Name View Source Status
0000950170-23-041314-index-headers.html Edgar Link pending
0000950170-23-041314-index.html Edgar Link pending
0000950170-23-041314.txt Edgar Link pending
0000950170-23-041314-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
spro-20230630.htm Edgar Link pending
spro-20230630.xsd Edgar Link pending
spro-ex10_1.htm Edgar Link pending
spro-20230630_def.xml Edgar Link unprocessable
spro-20230630_lab.xml Edgar Link unprocessable
spro-20230630_pre.xml Edgar Link unprocessable
spro-20230630_htm.xml Edgar Link completed
spro-ex10_2.htm Edgar Link pending
spro-ex10_3.htm Edgar Link pending
spro-ex10_4.htm Edgar Link pending
spro-ex31_1.htm Edgar Link pending
spro-ex31_2.htm Edgar Link pending
spro-ex32.htm Edgar Link pending
spro-20230630_cal.xml Edgar Link unprocessable